Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06129487 · ClinicalTrials.gov registry record · NA

Evaluations of Alcohol Warning Labels

A NA study of Esophageal Cancer and Alcohol Drinking, sponsored by University of Connecticut.

Completed
Registry status
NA
Development phase
1,053
Enrollment target
1
Study location

NCT06129487: Completed NA study of Esophageal Cancer and Alcohol Drinking, sponsored by University of Connecticut.

NCT06129487 is a NA study of Esophageal Cancer and Alcohol Drinking that has completed, run by University of Connecticut. The registered enrollment target is 1,053 participants, above the 491-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (114% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06129487, a NA study of Esophageal Cancer and Alcohol Drinking, has completed, sponsored by University of Connecticut.

COMPLETED
Registry status
NA
Development phase
1,053 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to determine the effectiveness of pictorial warning labels (PWLs) featuring narrative (vs. non-narrative) content in communicating the cancer risk of alcohol. Participants will be randomized to view either three narrative or non-narrative PWLs. Key outcome variables include visual attention, message reactance, risk perceptions, and intentions to reduce and stop drinking.

Primary Outcome

Dwell time measures the total duration of attention to an area of interest (AOI). Each warning label consisted of two AOIs: image AOI and text AOI. Dwell time for each AOI was averaged across three PWLs within each arm.

Interventions

  • BEHAVIORAL Narrative pictorial warning labels for alcoholic beverages
  • BEHAVIORAL Non-narrative pictorial warning labels for alcoholic beverages

Study Locations (1)

Connecticut

  • Online Survey-Experiment - Storrs

Trial Details

FieldValue
Enrollment Target 1,053 participants
Start Date 2024-01-19
Est. Completion 2024-03-27
Phase NA
University of Connecticut

107 total trials

What the finished NCT06129487 record still lists

NCT06129487 is an interventional study that assigns participants to a tested intervention. Its 1,053 participants enrollment target places it among the larger protocols in the corpus, above the 491-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (114% higher).

The record links to 4 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Narrative pictorial warning labels for alcoholic beverages is the first listed.

NCT06129487 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT06129487 about?

NCT06129487 is a clinical study titled "Evaluations of Alcohol Warning Labels". The goal of this study is to determine the effectiveness of pictorial warning labels (PWLs) featuring narrative (vs. non-narrative) content in communicating the cancer risk of alcohol. Participants will be randomized to view either three narrative or non-narrative PWLs. Key outcome variables include...

What is the current status of trial NCT06129487?

This trial is currently completed. It is a NA study. The enrollment target is 1,053 participants. The study started on 2024-01-19. Estimated completion is 2024-03-27.

What conditions does trial NCT06129487 study?

This clinical trial studies the following conditions: Esophageal Cancer, Alcohol Drinking, Oral Cancer, Larynx Cancer.

What interventions are being tested in trial NCT06129487?

The interventions under investigation include: Narrative pictorial warning labels for alcoholic beverages (BEHAVIORAL), Non-narrative pictorial warning labels for alcoholic beverages (BEHAVIORAL).

Who is sponsoring clinical trial NCT06129487?

This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06129487 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Esophageal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06129487's enrollment target sits among peer trials

1,053 12th of 123 higher than 112 of 123 other Esophageal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03242642 · 1,056 participants · NA

    Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

  • NCT04372108 · 1,056 participants

    A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

  • NCT04505618 · 1,050 participants · NA

    Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

  • NCT04511806 · 1,050 participants

    Childhood Cancer Predisposition Study (CCPS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06129487, the US trial registry maintained by the National Library of Medicine. NCT06129487 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.